# Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

> **NCT03254108** · NA · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 61 (actual)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **DRUG:** OPC-61815 injection 2mg
- **DRUG:** OPC-61815 injection 4mg
- **DRUG:** OPC-61815 injection 8mg
- **DRUG:** OPC-61815 injection 16mg
- **DRUG:** Tolvaptan tablet 15mg

## Key facts

- **NCT ID:** NCT03254108
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-06
- **Primary completion:** 2018-04-14
- **Final completion:** 2018-04-24
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254108, "Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03254108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*